High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells

High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells

Metformin, the most widely prescribed anti-diabetic drug, is shown to possess anti-cancer potential in treatment of cancers, including breast cancer; decreases breast cancer risk; and improves overall survival. However, reports suggest that higher glucose concentrations may negatively impact the ant...

Full description

Bibliographic Details
Main Authors:	Sharon Varghese, Samson Mathews Samuel, Elizabeth Varghese, Peter Kubatka, Dietrich Büsselberg
Format:	Article
Language:	English
Published:	MDPI AG 2019-01-01
Series:	Biomolecules
Subjects:	anti-cancer therapy breast cancer hyperglycemia/diabetes metformin triple negative breast cancers
Online Access:	http://www.mdpi.com/2218-273X/9/1/16

Similar Items

Metabolic heterogeneity in TNBCs: A potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy
by: Samson Mathews Samuel, et al.
Published: (2023-08-01)

Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells
by: Samson Mathews Samuel, et al.
Published: (2020-09-01)

Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells
by: Elizabeth Varghese, et al.
Published: (2018-12-01)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
by: Samson Mathews Samuel, et al.
Published: (2022-10-01)

The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers
by: Elizabeth Varghese, et al.
Published: (2018-09-01)

Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer
by: Elizabeth Varghese, et al.
Published: (2020-08-01)

Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells
by: Getinet M. Adinew, et al.
Published: (2022-05-01)

Metformin Therapy and Breast Cancer Incidence in the Ha’il Region
by: Mhdia Osman, et al.
Published: (2023-01-01)

Microarray analysis of breast cancer gene expression profiling in response to 2-deoxyglucose, metformin, and glucose starvation
by: Rita Aoun, et al.
Published: (2022-03-01)

A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

Metabolic Profiles Associated With Metformin Efficacy in Cancer
by: Sylvia Andrzejewski, et al.
Published: (2018-08-01)

Changes in the expression of cancer- and metastasis-related genes and proteins after metformin treatment under different metabolic conditions in endometrial cancer cells
by: Carsten Lange, et al.
Published: (2023-06-01)

Metabolic Health, Insulin, and Breast Cancer: Why Oncologists Should Care About Insulin
by: Lisa D. Yee, et al.
Published: (2020-02-01)

Antiproliferative Modulation and Pro-Apoptotic Effect of BR2 Tumor-Penetrating Peptide Formulation 2-Aminoethyl Dihydrogen Phosphate in Triple-Negative Breast Cancer
by: Laertty Garcia de Sousa Cabral, et al.
Published: (2023-11-01)

Anti-Proliferative and Pro-Apoptotic Effects Of Dipsacus Asperoides in a Cellular Model for Triple-Negative Breast Cancer
by: Nitin Telang, et al.
Published: (2022-01-01)

Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells
by: Leila Faramarzi, et al.
Published: (2019-12-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

Does triple negative breast cancer subtype carry poorer prognosis as compared to non-triple negative breast cancer lesion - A study from a tertiary hospital
by: Srijan Basu, et al.
Published: (2023-11-01)

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
by: Eva Kudelova, et al.
Published: (2022-11-01)

Could Metformin and Resveratrol Support Glioblastoma Treatment? A Mechanistic View at the Cellular Level
by: Raghad Sabaawi Ibrahim, et al.
Published: (2023-06-01)

Niosomal Delivery of Celecoxib and Metformin for Targeted Breast Cancer Treatment
by: Haneen A. Basheer, et al.
Published: (2023-10-01)

The antiproliferative potential and mechanism of action of metformin in MCF-7 cells
by: Zhibek Bekezhankyzy, et al.
Published: (2023-06-01)

Beyond renoprotective impact; ameliorative effects of metformin on malignancies
by: Nozar Dorestan, et al.
Published: (2018-05-01)

Fisetin-metformin co-loaded in mesoporous silica nanoparticles (MSNs) inhibited triple negative breast cancer proliferation
by: Mohammad Reza Karimzadeh, et al.
Published: (2023-10-01)

Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities
by: Sylvia Annabel Dass, et al.
Published: (2021-01-01)

Effects of Metformin on JNK Signaling Pathway and PD-L1 Expression in Triple Negative Breast Cancer
by: Wang R, et al.
Published: (2024-04-01)

Triple-negative breast cancer arising in a fibroadenoma in BRCA 1 mutated patient
by: Nicole Brunetti, et al.
Published: (2023-01-01)

Metformin Inducing the Change of Functional and Exhausted Phenotypic Tumor-Infiltrated Lymphocytes and the Correlation with JNK Signal Pathway in Triple-Negative Breast Cancer
by: Wang R, et al.
Published: (2022-12-01)

Ceramide Kinase (CERK) Emerges as a Common Therapeutic Target for Triple Positive and Triple Negative Breast Cancer Cells
by: Kajal Rajput, et al.
Published: (2022-09-01)

Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells
by: Gerke Ariaans, et al.
Published: (2017-03-01)

A case report and literature review on a rare subtype of triple-negative breast cancer in children
by: Lexiang Shi, et al.
Published: (2023-09-01)

Presentation and treatment of aggressive, Triple‐Negative carcinosarcoma of the breast
by: Niels Vizgan, et al.
Published: (2022-07-01)

Metformin and Breast Cancer: Current Findings and Future Perspectives from Preclinical and Clinical Studies
by: Karen A. Corleto, et al.
Published: (2024-03-01)

Metformin alleviates breast cancer through targeting high‐mobility group AT‐hook 2
by: Yang Li, et al.
Published: (2020-03-01)

Dual Effect of Combined Metformin and 2-Deoxy-D-Glucose Treatment on Mitochondrial Biogenesis and PD-L1 Expression in Triple-Negative Breast Cancer Cells
by: Jernej Repas, et al.
Published: (2022-03-01)

Clinical and histopathological characteristics associated with patients with triple-negative Breast cancer at a national reference hospital, 2012 - 2018
by: Giuliana Mandujano-Guizado, et al.
Published: (2019-06-01)

Metformin and Breast Cancer: Where Are We Now?
by: Mónica Cejuela, et al.
Published: (2022-02-01)

Androgen receptors: unclear ubiquitious mechanism or the missing key in the triple–negative breast cancer?
by: Ana Tečić-Vuger, et al.
Published: (2020-01-01)

TRIPLE TEST AND ALGORITHM IN DIAGNOSIS OF BREAST TUMORS
by: Türkan Rezanko
Published: (2008-07-01)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
by: Hana Kim, et al.
Published: (2021-11-01)